Is nerve growth factor a serum marker for neurological and psychiatric complications in Behcet's disease?

European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026

European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024

Epidemiology and treatment of Adamantiades-Behçet's disease in Germany: A healthcare claims database study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024

Sun exposure, a relevant exposome factor in acne patients and how photoprotection can improve outcomes.

Journal of cosmetic dermatology·2023

Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023

Inflammation and thrombo-occlusive vessel signalling in benign atrophic papulosis (Köhlmeier-Degos disease).

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Lancet (London, England)·2026

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Lancet (London, England)·2026

A trembling detour to the diagnosis of encephalitis: a neuroborreliosis case report.

Lancet (London, England)·2026

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial.

Lancet (London, England)·2026

Neurological Dysfunction During Contemporary Magnetically Levitated Left Ventricular Assist Device Support for Advanced Heart Failure: An STS-INTERMACS Analysis.

JACC. Heart failure·2026

Genes Do Not Read DSM: Tuberous Sclerosis Complex May Dominate with Multi-Neuropsychiatric Symptoms.

Harvard review of psychiatry·2026

Small Fiber Neuropathy.

Continuum (Minneapolis, Minn.)·2026

Amyloid Neuropathies.

Continuum (Minneapolis, Minn.)·2026

Diagnostic Approach to Neuropathy.

Continuum (Minneapolis, Minn.)·2026

Related Experiment Videos

Is nerve growth factor a serum marker for neurological and psychiatric complications in Behcet's disease?

Related Concept Videos

European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment.

European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.

Epidemiology and treatment of Adamantiades-Behçet's disease in Germany: A healthcare claims database study.

Sun exposure, a relevant exposome factor in acne patients and how photoprotection can improve outcomes.

Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa.

Inflammation and thrombo-occlusive vessel signalling in benign atrophic papulosis (Köhlmeier-Degos disease).

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

A trembling detour to the diagnosis of encephalitis: a neuroborreliosis case report.

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial.

Neurological Dysfunction During Contemporary Magnetically Levitated Left Ventricular Assist Device Support for Advanced Heart Failure: An STS-INTERMACS Analysis.

Genes Do Not Read DSM: Tuberous Sclerosis Complex May Dominate with Multi-Neuropsychiatric Symptoms.

Small Fiber Neuropathy.

Amyloid Neuropathies.

Diagnostic Approach to Neuropathy.

Related Experiment Videos

Is nerve growth factor a serum marker for neurological and psychiatric complications in Behcet's disease?

Related Concept Videos

Related Articles